<DOC>
	<DOCNO>NCT01581866</DOCNO>
	<brief_summary>The objective study compare rate extent absorption ziprasidone 20 mg capsule versus Geodon 20 mg capsule fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Ziprasidone HCL Capsules , 20 mg Under Fasting Conditions</brief_title>
	<detailed_description>Randomized , 2-way crossover , bioequivalence study Ziprasidone 20 mg capsule Geodon 20 mg capsule healthy subject fast condition .</detailed_description>
	<mesh_term>Ziprasidone</mesh_term>
	<criteria>Male female , smoker nonsmoker , 18 year age old . Capable consent . BMI 19.0 30.0 kg/m2 inclusively . Clinically significant illness within 4 week prior administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion Investigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive test hepatitis B , hepatitis C , HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 100 140 mmHg , diastolic blood pressure low 60 90 mmHg , heart rate less 60 100 bpm ) screening . Qtc &gt; 430 male Qtc &gt; 450 female . History significant alcohol abuse drug abuse within one year prior screen visit . Regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 Unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) . Use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen visit positive urine drug screen screen . History allergic reaction heparin , ziprasidone , relate drug . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , omeprazole ; examples inhibitor : antidepressant ( SSRI ) , cimetidine , diltiazem , macrolides , imidazole , neuroleptic , verapamil , fluoroquinolones , antihistamine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically significant history presence clinically significant neurological endocrinal cardiovascular , pulmonary , hematologic , immunologic , psychiatric , metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption hormonal contraceptive . Difficulty swallow study medication . Smoking 25 cigarette per day . Any food allergy , intolerance , restriction special diet , opinion Medical SubInvestigator , could contraindicate subject 's participation study . A depot injection implant drug ( hormonal contraceptive ) within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood ( exclude volume blood drawn screening procedure study ) prior administration study medication follow . 1 . 50 mL 300 mL whole blood within 30 day , 2 . 301 mL 500 mL whole blood within 45 day , 3. 500 mL whole blood within 56 day prior drug administration . Consumption food beverage contain grapefruit ( e.g . fresh , can , frozen ) within 7 day prior administration study medication . History known presence tardive dyskinesia . History neuroleptic malignant syndrome . History known presence clinically significant cardiac disease ( heart failure , QT prolongation , congenital long QT syndrome , myocardial infarction , cardiac arrhythmia , conduction abnormality ) condition electrolyte disturbance , hypokalemia hypomagnesemia . Breastfeeding subject . Positive urine pregnancy test screening . Female subject childbearing potential unprotected sexual intercourse nonsteril male partner ( i.e male sterilize vasectomy least 6 month ) within 14 day prior study drug administration . Acceptable method contraception . 1. intrauterine contraceptive device ( place least 4 week prior study drug administration ; 2. condom diaphragm + spermicide ; 3. hormonal contraceptive ( start least 4 week prior study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Ziprasidone hydrochloride</keyword>
	<keyword>crossover</keyword>
</DOC>